Initially funded by the European Commission’s Horizon 2020 programme, the first four ENABLE conferences were held in the cities hosting the headquarters of the four entities leading the project: the Institute for Research in Biomedicine (IRB Barcelona) in Barcelona, Spain; the Radboud Institute for Molecular Life Sciences (RIMLS) in Nijmegen, The Netherlands; The Novo Nordisk Foundation Center for Protein Research (CPR) in Copenhagen, Denmark; and the Scuola Europea di Medicina Molecolare (SEMM), in Milan, Italy. In this new cycle of conferences, FEBS, IUBMB and the four core ENABLE institutions have joined forces to share ENABLE best practices with other international research institutions. To this end, in addition to the four core research centres, other institutions can apply to become associated centres and host one of the events. For the 2024 event, FEBS-IUBMB-ENABLE will actively search for an associated centre in a non-European country to ensure that one of the events is held on another continent.

https://scholar.google.com/citations?user=p8dQbaUAAAAJ https://www.webofscience.com/wos/author/record/H-4020-2013 https://www.scopus.com/authid/detail.uri?authorId=55711821300 https://www.researchgate.net/profile/Maxim-Ponomarev https://orcid.org/0000-0002-7530-3116 https://en.wikipedia.org/wiki/List_of_plasma_physicists

'FEBS Communications' posts general items from the FEBS Network Team as well as news on FEBS events and other activities.

FEBS Letters is renowned both for its quality of content and speed of production. Bringing together the most important developments in the molecular biosciences, FEBS Letters provides an international forum for Reviews, Research Letters and Research Articles that merit urgent publication.

Dr. Isabel Varela-Nieto graduated and earned her doctorate in Chemistry, Biochemistry Section, at the University Complutense of Madrid (Spain). She has been a visiting guest scientist at the Medical Schools of Uppsala (FEBS Fellow, Sweden) and San Diego (MEC Sabbatical, USA). She is Professor of Research at the CSIC and group leader at the CIBER of rare diseases (CIBERER, ISCIII) in Madrid. From the early 1990s she has been studying hearing neurobiology and IGF-1 actions. She was the first Chair of the SEBBM Science for Society working group with which she actively collaborates, and member of the FEBS Network working group. She is currently the president of the SEBBM, a member of the FEBS Science and Society Committee and of the ISC Finances Committee.